IVFAustralia Selects Cryoport As Exclusive Supply Chain Solutions Provider

Sydney and Nashville, TN /PRNewswire/ - IVFAustralia, an Australian-based provider of full-service fertility care, IVF and related services as part of the Virtus Health network, and Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of innovative temperature-controlled supply chain solutions supporting the life sciences, reproductive medicine and animal health industries, today announced that IVFAustralia has selected Cryoport as its exclusive supply chain solutions partner for its global reproductive material shipments.

The multi-year agreement provides IVFAustralia and its fertility patients with the most advanced cryogenic shipping service in the world. Cryoport's ISO-certified risk mitigation process ensures safe, end-to-end transport of reproductive materials across the entire Virtus Health network.

"IVFAustralia is at the forefront of innovations that ensure risk mitigation for our patients," said Kate Munnings, CEO of Virtus Health. "Always employing the latest technologies and in keeping with the Fertility Society of Australia and New Zealand's issued recommendations around advanced data logging, chain of custody and condition monitoring that should be followed while transporting cryopreserved gametes and embryos, we have chosen Cryoport as our exclusive supply chain solutions provider. Its scientifically engineered shippers enable state-of-the-art GPS monitoring, internal temperature tracking and 24/7 logistics monitoring that meet the guidelines of the most rigorous regulatory agencies."

Jerrell Shelton, CEO of Cryoport, continued, "IVFAustralia is the first full-service fertility care company in Australia to embrace our best-in-class technology for safely transporting valuable reproductive materials for families around the globe. IVFAustralia is part of Virtus Health, the largest provider of fertility services in Australia and, with a growing presence in Singapore, Ireland, the United Kingdom and Denmark, our selection is a true testament to Cryoport's ability to provide the highest-quality services for fertility patients everywhere. We look forward to working closely with IVFAustralia to ensure that that every detail, from start to finish, is handled with the utmost care and protection it deserves."

About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the research, clinical and commercial spectrum. With 48 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform provides mission-critical solutions, services, and products to the biopharma/pharma, animal health, and reproductive medicine markets worldwide. In addition to its standard setting supply chain solutions, Cryoport is the world's largest manufacturer of cryogenic systems and one of the largest life science focused specialty couriers.

For more information, visit www.cryoport.com or follow @cryoport on Twitter at www.twitter.com/cryoport for live updates.

About Virtus Health
Virtus Health Limited brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care, IVF and related services. The company is the largest provider of fertility services in Australia, Ireland & Denmark with a growing presence in Singapore & the United Kingdom. Brands within the Virtus Health group include Queensland Fertility Group, IVFAustralia, Melbourne IVF, TasIVF, The Fertility Centre, Sims IVF, Complete Fertility, Trianglen Clinic, Aagaard Fertility Clinic and Virtus Fertility Centre in Singapore.

Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, plans, strategy, acquisitions, financial results and financial condition. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors discussed in the Company's Securities and Exchange Commission ("SEC") reports including, but not limited to, the Company's Annual Report on Form 10-K for the three and twelve months ended December 31, 2022 and any subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.